JP2022511568A5 - - Google Patents
Info
- Publication number
- JP2022511568A5 JP2022511568A5 JP2021533154A JP2021533154A JP2022511568A5 JP 2022511568 A5 JP2022511568 A5 JP 2022511568A5 JP 2021533154 A JP2021533154 A JP 2021533154A JP 2021533154 A JP2021533154 A JP 2021533154A JP 2022511568 A5 JP2022511568 A5 JP 2022511568A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024104638A JP2024129091A (ja) | 2018-12-11 | 2024-06-28 | 統合失調症及び他の神経精神障害の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862778145P | 2018-12-11 | 2018-12-11 | |
| US62/778,145 | 2018-12-11 | ||
| PCT/US2019/065742 WO2020123663A1 (en) | 2018-12-11 | 2019-12-11 | Methods of treating schizophrenia and other neuropsychiatric disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024104638A Division JP2024129091A (ja) | 2018-12-11 | 2024-06-28 | 統合失調症及び他の神経精神障害の治療方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022511568A JP2022511568A (ja) | 2022-01-31 |
| JPWO2020123663A5 JPWO2020123663A5 (https=) | 2022-12-15 |
| JP2022511568A5 true JP2022511568A5 (https=) | 2022-12-15 |
| JP7518547B2 JP7518547B2 (ja) | 2024-07-18 |
Family
ID=69160318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533154A Active JP7518547B2 (ja) | 2018-12-11 | 2019-12-11 | 統合失調症及び他の神経精神障害の治療方法 |
| JP2024104638A Pending JP2024129091A (ja) | 2018-12-11 | 2024-06-28 | 統合失調症及び他の神経精神障害の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024104638A Pending JP2024129091A (ja) | 2018-12-11 | 2024-06-28 | 統合失調症及び他の神経精神障害の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220025379A1 (https=) |
| EP (1) | EP3894556A1 (https=) |
| JP (2) | JP7518547B2 (https=) |
| CN (2) | CN119925614A (https=) |
| AU (1) | AU2019396450B2 (https=) |
| CA (1) | CA3122289A1 (https=) |
| WO (1) | WO2020123663A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110011658A (ko) | 2008-05-08 | 2011-02-08 | 유니버시티 오브 로체스터 | 최적화된 세포 제제에 의한 수초 질환의 치료 |
| EP2954046B1 (en) | 2013-02-06 | 2025-10-15 | University Of Rochester | Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders |
| US9724432B2 (en) | 2015-04-30 | 2017-08-08 | University Of Rochester | Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder |
| JP7457505B2 (ja) | 2017-05-10 | 2024-03-28 | ユニバーシティー オブ ロチェスター | 神経精神障害を処置する方法 |
| WO2019246262A2 (en) | 2018-06-21 | 2019-12-26 | University Of Rochester | Methods of treating or inhibiting onset of huntington's disease |
| CN116350758B (zh) * | 2023-03-16 | 2024-08-06 | 郑州大学 | 肿瘤共享新抗原表位肽或其编码核酸在制备药物中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6838283B2 (en) | 1998-09-29 | 2005-01-04 | Isis Pharmaceuticals Inc. | Antisense modulation of survivin expression |
| CZ296576B6 (cs) | 1999-02-12 | 2006-04-12 | Sankyo Company Limited | Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem |
| US6013787A (en) | 1999-02-23 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense modulation of Smad4 expression |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| US7179796B2 (en) | 2000-01-18 | 2007-02-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
| AU2003260370B2 (en) | 2002-08-05 | 2008-05-22 | Silence Therapeutics Gmbh | Further novel forms of interfering RNA molecules |
| KR100750788B1 (ko) | 2003-09-18 | 2007-08-20 | 아이시스 파마수티컬즈 인코포레이티드 | ｅＩＦ4Ｅ 발현의 조정 |
| AU2005252663B2 (en) | 2004-06-03 | 2011-07-07 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| US7128264B2 (en) | 2004-07-23 | 2006-10-31 | Symbol Technologies, Inc: | Electro-optical reader with improved performance in high intensity ambient light |
| JP4428296B2 (ja) | 2005-06-10 | 2010-03-10 | セイコーエプソン株式会社 | 表示パネルモジュールおよび表示装置 |
| US9962558B2 (en) * | 2005-08-05 | 2018-05-08 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
| BRPI0619794B8 (pt) | 2005-12-13 | 2022-06-14 | Univ Kyoto | Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas |
| DK3399025T3 (da) | 2007-03-23 | 2025-06-16 | Wisconsin Alumni Res Found | Omprogrammering af somatiske celler |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| US10047346B2 (en) | 2008-08-08 | 2018-08-14 | Mayo Foundation For Medical Education And Research | Method of treating heart tissue using induced pluripotent stem cells |
| US20120276070A1 (en) | 2009-11-17 | 2012-11-01 | Vitro Diagnositics, Inc. | Induced Pluripotent Stem Cells and Related Methods |
| US9005967B2 (en) | 2010-01-22 | 2015-04-14 | Kyoto University | Myc variants improve induced pluripotent stem cell generation efficiency |
| EP2723861A4 (en) * | 2011-06-21 | 2014-12-10 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION |
| PT2773748T (pt) * | 2011-11-04 | 2020-03-26 | Memorial Sloan Kettering Cancer Center | Neurónios dopaminérgicos (da) do mesencéfalo para enxerto |
| US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
| WO2016115558A2 (en) | 2015-01-16 | 2016-07-21 | Bruno Doiron | Compositions and methods for creating pancreatic cancer animal model |
-
2019
- 2019-12-11 CA CA3122289A patent/CA3122289A1/en active Pending
- 2019-12-11 AU AU2019396450A patent/AU2019396450B2/en active Active
- 2019-12-11 CN CN202510144182.8A patent/CN119925614A/zh active Pending
- 2019-12-11 US US17/413,384 patent/US20220025379A1/en active Pending
- 2019-12-11 WO PCT/US2019/065742 patent/WO2020123663A1/en not_active Ceased
- 2019-12-11 EP EP19836294.9A patent/EP3894556A1/en active Pending
- 2019-12-11 CN CN201980091600.4A patent/CN113728103B/zh active Active
- 2019-12-11 JP JP2021533154A patent/JP7518547B2/ja active Active
-
2024
- 2024-06-28 JP JP2024104638A patent/JP2024129091A/ja active Pending